Merck Advances Oral Drug Trials and Invests in Cancer Therapy

Merck, also known as MSD, has entered a new phase of development for oral drug delivery technology, advancing Cyprumed's platform to clinical trials. The company has initiated Phase I studies, signaling progress in exploring new methods for administering therapies.

In a separate move, Merck has committed a substantial investment of $2.13 billion to SciBrunch for its KRAS (ON) inhibitor. This strategic investment highlights the company's focus on developing novel cancer treatments targeting specific genetic mutations.

These advancements occur against the backdrop of a recent withdrawal of a cancer drug filing by Merck. Coverage today notes that this withdrawal has prompted discussions about the ongoing potential and future of the drug in question.

Merck is also positioned within the broader small molecule drug discovery market, which is projected to experience significant growth. Reports forecast the market expanding from $61.5 billion in 2024 to $100 billion by 2030, with Merck identified as a key player alongside other major pharmaceutical companies.